Ovid Therapeutics (OVID) Free Cash Flow Growth (1y) (2017 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Free Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 125.17% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 96.00% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1,829.52% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -268.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -268.66% |
| Mar 31, 2026 | -35.21% |
| Dec 31, 2025 | -4.27% |
| Sep 30, 2025 | 14.23% |
| Jun 30, 2025 | 66.74% |
| Mar 31, 2025 | 38.46% |
| Dec 31, 2024 | 16.10% |
| Sep 30, 2024 | -49.29% |
| Jun 30, 2024 | -21.61% |
| Mar 31, 2024 | -37.76% |
| Dec 31, 2023 | -28.00% |
| Sep 30, 2023 | 20.82% |
| Jun 30, 2023 | 17.63% |
| Mar 31, 2023 | 39.77% |
| Dec 31, 2022 | 23.56% |
| Sep 30, 2022 | -16.65% |
| Jun 30, 2022 | 26.21% |
| Mar 31, 2022 | -112.51% |
| Dec 31, 2021 | 16.47% |
| Sep 30, 2021 | -629.18% |